TNF and amyotrophic lateral sclerosis: A study conducted in 2019 assessed a potential link between the administration of TNF-α inhibitors for various periods (12-120 months) and the risk of ALS [36]; the study revealed that the first symptoms of ALS occurred after 12 to 18 months of treatment with TNF-α inhibitors with a strong association between drug exposure and ALS development.